| Drug Name: | Glycopyrrolate |
| Manufacturer: | Kali Laboratories, Inc. A Wholly Owned Subsidiary of Par Pharmaceutical Companies Inc. |
| Other Info: | |
| Clinical Trials: | |
Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.
Glycopyrrolate tablets are contraindicated in those patients with a hypersensitivity to glycopyrrolate.In the presence of a high environmental temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur with use of glycopyrrolate.Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomyor colostomy.
In this instance treatment with this drug would be inappropriate and possibly harmful.Glycopyrrolate may produce drowsiness and blurred vision.
In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery, or performing hazardous work while taking this drug.Theoretically, with overdosage, a curare-like action may occur, i.e., neuro-muscular blockade leading to muscular weakness and possible paralysis.